MedPath

BRISTOL MYERS SQUIBB

๐Ÿ‡ซ๐Ÿ‡ทFrance
Ownership
-
Established
1989-01-01
Employees
30K
Market Cap
$97.5B
Website
https://www.bms.com/

A Study to Provide a Better Understanding of Baraclude's Pharmacokinetic Properties in a Real World Clinical Setting

Phase 1
Completed
Conditions
Hepatitis B Virus
Interventions
First Posted Date
2017-03-20
Last Posted Date
2023-11-18
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
6
Registration Number
NCT03083821
Locations
๐Ÿ‡ฏ๐Ÿ‡ต

Local Institution, Hachioji-shi, Tokyo, Japan

Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy

Completed
Conditions
Hepatitis C
First Posted Date
2017-03-06
Last Posted Date
2022-02-23
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
344
Registration Number
NCT03071133
Locations
๐Ÿ‡ฏ๐Ÿ‡ต

Local Institution, Tokyo, Japan

An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma

Phase 3
Completed
Conditions
Melanoma
Interventions
Biological: nivolumab
Biological: ipilimumab
First Posted Date
2017-03-01
Last Posted Date
2021-09-20
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
1844
Registration Number
NCT03068455
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States

๐Ÿ‡ฎ๐Ÿ‡น

Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy

๐Ÿ‡ฎ๐Ÿ‡น

Istituto Oncologico Veneto IOV, Padova, Italy

and more 67 locations

Relative Bioavailability of BMS-931699 From Prefilled Syringe Compared to Drug in Vial

Phase 1
Terminated
Conditions
Healthy
Interventions
First Posted Date
2017-02-23
Last Posted Date
2017-12-20
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
5
Registration Number
NCT03058822
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Qps-Mra, Llc, South Miami, Florida, United States

A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer

Phase 3
Withdrawn
Conditions
Non-Small Cell Lung Cancer
Interventions
First Posted Date
2017-02-09
Last Posted Date
2018-04-17
Lead Sponsor
Bristol-Myers Squibb
Registration Number
NCT03048136
Locations
๐Ÿ‡ต๐Ÿ‡ช

Local Institution, Lima, Peru

Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Completed
Conditions
Chronic Phase Chronic Myeloid Leukemia
First Posted Date
2017-02-07
Last Posted Date
2022-12-21
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
118
Registration Number
NCT03045120
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Mount Sinai Hospital, Chicago, Illinois, United States

๐Ÿ‡บ๐Ÿ‡ธ

Alexian Brothers Medical Center, Elk Grove Village, Illinois, United States

๐Ÿ‡บ๐Ÿ‡ธ

The Cancer Institute At Alexian Brothers, Elk Grove Village, Illinois, United States

and more 20 locations

Effect of BMS-986165 on the Pharmacokinetics of Rosuvastatin

Phase 1
Completed
Conditions
Inflammatory Diseases
Autoimmune Diseases
Interventions
First Posted Date
2017-02-07
Last Posted Date
2017-04-17
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
20
Registration Number
NCT03044873
Locations
๐Ÿ‡บ๐Ÿ‡ธ

PPD Phase I Clinic, Austin, Texas, United States

A Multiple Dose Study to Assess the Safety and Tolerability of BMS-986166 in Healthy Volunteers

Phase 1
Completed
Conditions
Ulcerative Colitis
Interventions
Drug: BMS-986166
Other: Placebo matching BMS-986166
First Posted Date
2017-02-01
Last Posted Date
2019-01-30
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
213
Registration Number
NCT03038711
Locations
๐Ÿ‡บ๐Ÿ‡ธ

PPD Development, LLC, Austin, Texas, United States

Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer

Phase 3
Active, not recruiting
Conditions
Urothelial Cancer
Interventions
First Posted Date
2017-01-30
Last Posted Date
2024-10-23
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
1322
Registration Number
NCT03036098
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Local Institution - 0001, Anchorage, Alaska, United States

๐Ÿ‡บ๐Ÿ‡ธ

Local Institution - 0115, Fresno, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

St Joseph Heritage Healthcare, Santa Rosa, California, United States

and more 171 locations
ยฉ Copyright 2025. All Rights Reserved by MedPath